Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Hyun Joo Shin"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Pediatric cancer
Children’s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) System for Pediatric Patients with Hepatoblastoma: A Retrospective, Hospital-Based Cohort Study in South Korea
Pyeong Hwa Kim, Hyun Joo Shin, Hee Mang Yoon, Young Hun Choi, Jung-Man Namgoong, Dae Yeon Kim, Kyung-Nam Koh, Mi-Jung Lee, Haesung Yoon, Chuhl Joo Lyu, Jung Woo Han, Seung Min Hahn, Young Ah Cho
Cancer Res Treat. 2022;54(1):253-258.   Published online March 24, 2021
DOI: https://doi.org/10.4143/crt.2021.265
AbstractAbstract PDFPubReaderePub
Purpose
In 2017, the Children’s Hepatic Tumors International Collaboration-Hepatoblastoma Stratification (CHIC-HS) system was introduced. We aimed to evaluate the accuracy of CHIC-HS System for the prediction of event-free survival (EFS) in Korean pediatric patients with hepatoblastoma.
Materials and Methods
This two-center retrospective study included consecutive Korean pediatric patients with histopathologically confirmed hepatoblastoma from March 1988 through September 2019. We compared EFS among four risk groups according to the CHIC-HS system. Discriminatory ability of CHIC-HS system was also evaluated using optimism-corrected C-statistics. Factors associated with EFS were explored using multivariable Cox regression analysis.
Results
We included 129 patients (mean age, 2.6±3.3 years; female:male, 63:66). The 5-year EFS rates in the very low, low, intermediate, and high-risk groups, according to the CHIC-HS system were 90.0%, 82.8%, 73.5%, and 51.3%, respectively. The CHIC-HS system aligned significantly well with EFS outcomes (p=0.004). The optimism-corrected C index of CHIC-HS was 0.644 (95% confidence interval [CI], 0.561 to 0.727). Age ≥ 8 (vs. age ≤ 2; hazard ratio [HR], 2.781; 95% CI, 1.187 to 6.512; p=0.018), PRE-Treatment EXTent of tumor (PRETEXT) stage IV (vs. PRETEXT I or II; HR, 2.774; 95% CI, 1.228 to 5.974; p=0.009), and presence of metastasis (HR, 2.886; 95% CI, 1.457 to 5.719; p=0.002), which are incorporated as the first three nodes in the CHIC-HS system, were independently associated with EFS.
Conclusion
The CHIC-HS system aligned significantly well with EFS outcomes in Korean pediatric patients with hepatoblastoma. Age group, PRETEXT stage, and presence of metastasis were independently associated with EFS.

Citations

Citations to this article as recorded by  
  • Elevated serum uric acid is associated with the risk of advanced staging and vascular involvement in patients with hepatoblastoma: a 14-year retrospective study
    Yunlan Zhou, Jinning Li, Yanhui Ma, Mengjie Tang, Xiaojun Yuan, Lisong Shen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • 6,246 View
  • 211 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea
Moo Hyun Lee, Wonshik Han, Jeong Eon Lee, Ku Sang Kim, Heeseung Park, Jongjin Kim, Soo Youn Bae, Hyun Joo Shin, Jong Won Lee, Eun Sook Lee
Cancer Res Treat. 2015;47(2):208-214.   Published online September 11, 2014
DOI: https://doi.org/10.4143/crt.2013.223
AbstractAbstract PDFPubReaderePub
Purpose
The 21-gene (Oncotype DX) recurrence score (RS) assay is useful in predicting the benefits of adjuvant chemotherapy for early breast cancer patients and is widely used in Western countries. However, to date, it has not gained much popularity in East Asia. We analyzed the results from five institutions’ experience from using the 21-gene assay and examined the impact of assay results on decision making of chemotherapy in Korean breast cancer patients and the associations between RS and clinicopathologic characteristics.
Materials and Methods
The 21-gene assay was performed on 212 patients with estrogen receptor-positive early breast cancer in five institutions. Each center made systemic treatment decisions both before and after the knowledge of assay results.
Results
Among the 212 patients, 132 (62.3%) had a low RS of < 18, 60 (28.3%) had an intermediate RS of 18-30, and 20 (9.4%) had a high RS of ≥ 31. Histologic grade, presence of micrometastases, Ki-67, and presence of lymphatic invasion were statistically associated with the RS results. Treatment decisions were changed in 115 of 212 patients (54.2%) in 109 of 212 (51.4%) from chemotherapy plus hormone therapy to hormone therapy, and in six of 212 (2.8%) from hormone therapy to chemotherapy plus hormone therapy.
Conclusion
The 21-gene breast cancer assay proved to have a significant impact on treatment decision- making. The test reduces chemotherapy use in more than 50% of Korean estrogen receptor-positive, early breast cancer patients.

Citations

Citations to this article as recorded by  
  • The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing
    Bradley M. Turner, Brian S. Finkelman, David G. Hicks, Numbere Numbereye, Ioana Moisini, Ajay Dhakal, Kristin Skinner, Mary Ann G. Sanders, Xi Wang, Michelle Shayne, Linda Schiffhauer, Hani Katerji, Huina Zhang
    Cancers.2023; 15(3): 903.     CrossRef
  • Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
    Yufei Zeng, Weiqi Gao, Xiaosong Chen, Kunwei Shen
    British Journal of Cancer.2021; 124(5): 975.     CrossRef
  • Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada
    Simon Gagnet, Caroline Diorio, Louise Provencher, Cynthia Mbuya-Bienge, Julie Lapointe, Claudya Morin, Julie Lemieux, Hermann Nabi
    Journal of Personalized Medicine.2021; 11(9): 858.     CrossRef
  • Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach
    Bradley M. Turner, Hani Katerji, Huina Zhang, David G. Hicks
    Human Pathology Reports.2021; 26: 300574.     CrossRef
  • Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer
    Shin Hye Yoo, Tae-Yong Kim, Miso Kim, Kyung-Hun Lee, Eunshin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Sae-Won Han, Tae-You Kim, Seock-Ah Im
    Clinical Breast Cancer.2020; 20(2): 98.     CrossRef
  • Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer
    Yufei Zeng, Weiqi Gao, Lin Lin, Xiaosong Chen, Kunwei Shen
    Journal of Geriatric Oncology.2020; 11(5): 843.     CrossRef
  • Prognostic Factors of Disease Recurrence in Breast Cancer Using Quantitative and Qualitative Magnetic Resonance Imaging (MRI) Parameters
    Jeongmin Lee, Sung Hun Kim, Bong Joo Kang
    Scientific Reports.2020;[Epub]     CrossRef
  • The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool
    Anna Olsson-Brown, Pavlos Piskilidis, Julie O'Hagan, Nicky Thorp, Peter Robson, Helen Innes, Helen Wong, Silvia Cicconi, Richard Jackson, Tamara Kiernan, Christopher Holcombe, Susan O'Reilly, Carlo Palmieri
    The Breast.2019; 44: 94.     CrossRef
  • Clinical significance of 21-gene recurrence score assay for hormone receptor–positive, lymph node-negative breast cancer in early stage
    Yang Yu-qing, Wang Lei, Huang Mei-ling, Xiao Jing-jing, Wei Mei-chen, Wu Jiang, Hao Jun-sheng, Ling Rui, Li Nan-lin
    Experimental and Molecular Pathology.2019; 108: 150.     CrossRef
  • Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis
    Sue Harnan, Paul Tappenden, Katy Cooper, John Stevens, Alice Bessey, Rachid Rafia, Sue Ward, Ruth Wong, Robert C Stein, Janet Brown
    Health Technology Assessment.2019; 23(30): 1.     CrossRef
  • Uptake of the 21-Gene Assay Among Women With Node-Positive, Hormone Receptor−Positive Breast Cancer
    Megan C. Roberts, Allison W. Kurian, Valentina I. Petkov
    Journal of the National Comprehensive Cancer Network.2019; 17(6): 662.     CrossRef
  • Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26–30
    Seho Park, Yunan Han, Ying Liu, Adetunji T. Toriola, Lindsay L. Peterson, Graham A. Colditz, Seung Il Kim, Young Up Cho, Byeong-Woo Park, Yikyung Park
    Breast Cancer Research.2019;[Epub]     CrossRef
  • Clinical analysis of 21‑gene recurrence score test in hormone receptor‑positive early‑stage breast cancer
    Lizhe Zhu, Nan Ma, Bin Wang, Can Zhou, Yu Yan, Ke Wang, Jianjun He, Yu Ren
    Oncology Letters.2019;[Epub]     CrossRef
  • Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe
    E.J. Blok, E. Bastiaannet, W.B. van den Hout, G.J. Liefers, V.T.H.B.M. Smit, J.R. Kroep, C.J.H. van de Velde
    Cancer Treatment Reviews.2018; 62: 74.     CrossRef
  • Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
    Jae-Myung Kim, Jai Min Ryu, Isaac Kim, Hee Jun Choi, Seok Jin Nam, Seok Won Kim, Jonghan Yu, Se Kyung Lee, Jeong Eon Lee
    Journal of Breast Cancer.2018; 21(2): 222.     CrossRef
  • Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay
    Soo Jin Park, Moo Hyun Lee, Sun-Young Kong, Mi Kyung Song, Jungnam Joo, Youngmee Kwon, Eun-Gyeong Lee, Jai Hong Han, Sung Hoon Sim, So-Youn Jung, Seeyoun Lee, Keun Seok Lee, In Hae Park, Eun Sook Lee
    Breast Cancer Research and Treatment.2018; 170(1): 69.     CrossRef
  • Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores
    Jonathan Chen, Xian Wu, Paul J. Christos, Silvia Formenti, Himanshu Nagar
    Breast Cancer Research.2018;[Epub]     CrossRef
  • Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer
    Jai Min Ryu, Hee Jun Choi, Isaac Kim, Se Kyung Lee, Jonghan Yu, Jee-Eun Kim, Byeong-il Kang, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim
    Breast Cancer Research and Treatment.2018; 172(3): 627.     CrossRef
  • Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
    Jinkyoung Kim, Aeree Kim, Chungyeul Kim
    Oncology Letters.2018;[Epub]     CrossRef
  • Impact d’un test de signature génomique en sénologie sur les décisions en réunion de concertation pluridisciplinaire : une expérience française
    C. Dreyfus, M. Ballester, J. Gligorov, P. Agranat, M. Antoine, I. Tengher, A. Bricou
    Gynécologie Obstétrique & Fertilité.2015; 43(12): 780.     CrossRef
  • 12,996 View
  • 127 Download
  • 25 Web of Science
  • 20 Crossref
Close layer
Laparoscopic Assisted Distal Rectal Cancer Resection with Preoperative Concurrent Chemoradiotherapy
Bong Hwa Lee, Mi Young Chang, Sung Kook Park, Taeik Eum, Hyun Joo Shin, Nam Kyu Ro, Chang Nam An, Hae Wan Lee, Lee Su Kim, Hyoung-Chul Park, Hoon Sik Bae, Dae Young Zang, Richard L Whelan
Cancer Res Treat. 2007;39(1):10-15.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.10
AbstractAbstract PDFPubReaderePub
Purpose

Anatomy of deep pelvis, narrow distal margin and tumor invasion into neighbor organ are obstacles for curative radical resection for advanced cancer of distal rectum. Technically, laparoscopic application after downstaging the tumor with preoperative concurrent chemotherapy (CCRT) may give a solution to overcome the anatomical difficulties. We compared the results of laparoscopic surgery in the patients who received CCRT with those of patients who had conventional surgery.

Materials and Methods

A continuous infusion of 5FU plus leucovorin and radiotherapy (50.4 Gy) in 28 fractions was given each patient as CCRT. They underwent D2 radical resection with TME and ANP for the rectal cancer in 4 weeks.

Results

Thirty three patients had laparoscopic resection such as LAR, colo-anal anastomosis and APR. The results were compared with 12 cases of the conventional resections. As a result of preoperative CCRT, the cancer was down-staged in 71%. Two year disease free survival was 75% and 74% in the group of conventional and laparoscopic resection, respectively (p=0.427). Ileus, voiding difficulty and leakage after surgery were not different between two groups. Weakness of ejaculation was noted in 9~11% of both groups. The DFS of the preoperative CCRT followed by radical resection in the groups with a response was more favorable than that in the group with progressive or stable disease.

Conclusion

Radical resection of advanced distal rectal cancer could be done with performing a laparoscopic assisted operation after CCRT induced down-staging. We may suggest that laparoscopic assisted resection is a good treatment option as it doesn't increase the complications and it has a compatible survival rate to conventional surgery.

Citations

Citations to this article as recorded by  
  • DPYD,TYMS,TYMP,TK1, andTK2Genetic Expressions as Response Markers in Locally Advanced Rectal Cancer Patients Treated with Fluoropyrimidine-Based Chemoradiotherapy
    Ming-Yii Huang, Chan-Han Wu, Chun-Ming Huang, Fu-Yen Chung, Ching-Wen Huang, Hsiang-Lin Tsai, Chin-Fan Chen, Shiu-Ru Lin, Jaw-Yuan Wang
    BioMed Research International.2013; 2013: 1.     CrossRef
  • 9,643 View
  • 48 Download
  • 1 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP